Purity | Size | Price | VIP Price | USA Stock *0-1 Day | Global Stock *5-7 Days | Quantity | |||||
{[ item.p_purity ]} | {[ item.pr_size ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} |
{[ getRatePrice(item.pr_usd, 1,1) ]} | Inquiry {[ getRatePrice(item.pr_usd,item.pr_rate,item.mem_rate) ]} {[ getRatePrice(item.pr_usd,1,item.mem_rate) ]} | {[ item.pr_usastock ]} | Inquiry - | {[ item.pr_chinastock ]} | Inquiry - |
* Storage: {[proInfo.prStorage]}
CAS No. : | 22204-53-1 | MDL No. : | MFCD00010500 |
Formula : | C14H14O3 | Boiling Point : | - |
Linear Structure Formula : | - | InChI Key : | - |
M.W : | 230.26 | Pubchem ID : | - |
Synonyms : |
(S)-Naproxen;(+)-Naproxen;Napratec;Naposin;CG 3117
|
Num. heavy atoms : | 17 |
Num. arom. heavy atoms : | 10 |
Fraction Csp3 : | 0.21 |
Num. rotatable bonds : | 3 |
Num. H-bond acceptors : | 3.0 |
Num. H-bond donors : | 1.0 |
Molar Refractivity : | 66.79 |
TPSA : | 46.53 Ų |
GI absorption : | High |
BBB permeant : | Yes |
P-gp substrate : | No |
CYP1A2 inhibitor : | No |
CYP2C19 inhibitor : | No |
CYP2C9 inhibitor : | No |
CYP2D6 inhibitor : | No |
CYP3A4 inhibitor : | No |
Log Kp (skin permeation) : | -5.33 cm/s |
Log Po/w (iLOGP) : | 1.95 |
Log Po/w (XLOGP3) : | 3.34 |
Log Po/w (WLOGP) : | 3.04 |
Log Po/w (MLOGP) : | 2.57 |
Log Po/w (SILICOS-IT) : | 2.9 |
Consensus Log Po/w : | 2.76 |
Lipinski : | 0.0 |
Ghose : | None |
Veber : | 0.0 |
Egan : | 0.0 |
Muegge : | 0.0 |
Bioavailability Score : | 0.56 |
Log S (ESOL) : | -3.61 |
Solubility : | 0.0566 mg/ml ; 0.000246 mol/l |
Class : | Soluble |
Log S (Ali) : | -3.99 |
Solubility : | 0.0233 mg/ml ; 0.000101 mol/l |
Class : | Soluble |
Log S (SILICOS-IT) : | -4.02 |
Solubility : | 0.0221 mg/ml ; 0.0000962 mol/l |
Class : | Moderately soluble |
PAINS : | 0.0 alert |
Brenk : | 0.0 alert |
Leadlikeness : | 1.0 |
Synthetic accessibility : | 1.85 |
Signal Word: | Warning | Class: | N/A |
Precautionary Statements: | P201-P202-P261-P264-P270-P271-P280-P301+P312+P330-P302+P352-P304+P340+P312-P305+P351+P338-P308+P313-P332+P313-P337+P313-P403+P233-P405-P501 | UN#: | N/A |
Hazard Statements: | H302-H315-H319-H335-H361 | Packing Group: | N/A |
GHS Pictogram: |
* All experimental methods are cited from the reference, please refer to the original source for details. We do not guarantee the accuracy of the content in the reference.
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
88% | With dmap; dicyclohexyl-carbodiimide In dichloromethane 1.) 0 deg C, 1 h, 2.) r.t., 6 h; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With Thermotoga maritima esterase Tm1160; In aq. acetate buffer; at 70℃;pH 5.5;Enzymatic reaction; | General procedure: Enzymatic reactions were carried out at 70 C in 1 ml of a reaction mixture containing the purified enzyme (0.235 mg) and 25 mg of racemic ketoprofen ethyl ester dissolved in 50 mM sodium acetate buffer (pH 5.5). The reaction mixture was stirred at 200 rpm. The resulting solution was analyzed by HPLC using the chiral column (25 cm × 4.6 cm, Daical Chemical Industries, Tokyo, Japan). Samples were eluted with n-hexane:2-propanol:acetic acid (90:10:0.5, v/v/v) at a flow rate of 1.0 mL/min and detected at 254 nm. The retention times of racemic ketoprofen ethyl ester, R-ketoprofen, and S-ketoprofen were detected at 5.4, 14.8 and 18.2 min, respectively. The enantioselectivity of the enzyme was calculated with E = ln[1 - c(1 + eep)]/ln[1 - c(1 - eep)], where c and eep represent the degree of conversion and the enantiomeric excess of product, respectively [34]. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With C70H72IrO4P2(1+)*BF4(1-); hydrogen; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; under 3750.38 Torr; for 16h;Autoclave; | General procedure: The diastereomeric ratio of the used catalysts was determined by NMR prior to the catalysis. All catalysts and small amounts of liquids were added to the reaction mixture by means of stock solutions. All stock solutions were prepared using anhydrous, degassed solvents. In general, the hydrogenation reactions were carried out using anhydrous, degassed solvents. The catalyst solution, the substrate and, if applicable, the additive were solved in a Schlenk flask in the same solvent used for the stock solutions. A stainless steel autoclave loaded with a NMR tube and a small stirring bar was evacuated and flushed with argon three times before the reaction mixture was transferred into the NMR tube. As soon as the hydrogen gas line was purged with hydrogen gas at least seven times, the autoclave was pressurized with hydrogen gas. After the indicated period of time, the hydrogen gas was discharged from the autoclave. The conversion of the reaction was determined by NMR and the enantiomeric ratio of the product by enantioselective HPLC analysis. | |
With C72H64IrO6P2(1+)*BF4(1-); hydrogen; N-ethyl-N,N-diisopropylamine; In dichloromethane; at 20℃; under 3750.38 Torr; for 16h;Autoclave; | General procedure: The diastereomeric ratio of the used catalysts was determined by NMR prior to the catalysis. All catalysts and small amounts of liquids were added to the reaction mixture by means of stock solutions. All stock solutions were prepared using anhydrous, degassed solvents. In general, the hydrogenation reactions were carried out using anhydrous, degassed solvents. The catalyst solution, the substrate and, if applicable, the additive were solved in a Schlenk flask in the same solvent used for the stock solutions. A stainless steel autoclave loaded with a NMR tube and a small stirring bar was evacuated and flushed with argon three times before the reaction mixture was transferred into the NMR tube. As soon as the hydrogen gas line was purged with hydrogen gas at least seven times, the autoclave was pressurized with hydrogen gas. After the indicated period of time, the hydrogen gas was discharged from the autoclave. The conversion of the reaction was determined by NMR and the enantiomeric ratio of the product by enantioselective HPLC analysis. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
100% | With thionyl chloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 1h; Glovebox; Inert atmosphere; | |
97% | With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 0 - 25℃; | |
96% | With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 0 - 20℃; for 12h; Inert atmosphere; |
95% | With thionyl chloride In dichloromethane for 3h; | 4.1.6 Synthesis of cis-(±)-4-chloro-6-(naphthalen-1-yl)-tetrahydro-2H-pyran-2-yl)methyl 2-(6-methoxynaphthalen-2-yl)propanoate (8) The reaction was performed by stirring a solution of naproxen (2.0g) in SOCl2 (5.0mL) and the mixture was stirred at room temperature at 80°C for 3h. After the end of reaction (verified by chromatography using hexane: ethyl acetate (7:3) as solvent), the resulting mixture on evaporation afforded naproxen chloride in 95% yield. 1mmol of naproxen chloride and 1mmol of alcohol (±)- 3 were stirred in 10mL of THF and 0.5mL of TEA at 80°C for 7days. After the end of reaction (verified by chromatography), the resulting mixture was extracted with CH2Cl2 (3×20mL). Pure product was obtained from the crude reaction by column chromatography through silica gel, using AcOEt:hexane as solvent in a ratio of 3:7. The solvent mixture was concentrated under reduced pressure to afford 8 in 74% yield; IR (KBr, cm-1): 825 and 800 (C-H aromatics); 1327-1178 (C-O); 1600 and 1500 (C=C aromatics); 1730 (C=O ester); 2970 (C-H sp3). 1H NMR (CDCl3, 400MHz) δ: 0.84 (t, 2H); 1.24 (m, 1H); 1.59 (m, 5H); 1.71 (m, 2H); 3.44 (m, 1H); 3.87 (m, 1H); 4.01 (s, 3H); 4.04 (m, 1H); 4.10 (m, 2H); 7.28 (m, 2H); 7.52 (m, 4H); 7.70 (m, 5H); 8.17 (d, 2H). 13C NMR (101MHz; CDCl3) δ: 10.29; 18.32; 18.43; 21.91; 25.93; 28.97; 44.41; 45.30; 56.97; 63.98; 66.44; 113.88; 113.94; 116.73; 123.88; 123.97; 126.12; 126.13; 127.39; 127.49; 127.81; 129.45; 129.50; 130.99; 131.03; 136.41; 136.63; 152.75; 174.50. Anal. Calcd for C32H29ClO4: C, 74.92; H, 5.70. Found: C, 74.85; H, 5.62. |
94% | With phosgene In dichloromethane at 20 - 25℃; for 1.83333h; | 2 Example 2Example 1 was repeated with the differences given in table 2._Example 1 To a suspension of compound of formula (II-down) (30.5 g, 132.4 mmol), DCM as solvent (78 ml) and DMF as catalyst (0.51 g, 7.0 mmol) at 20 to 25°C, phosgene as chlorination agent (25.6 g / 258.8 mmol) was added in 20 min. The mixture was stirred at 20 to 25°C for 1.5 h (conversion 99%). The DCM was distilled off at an inner temperature of 35 to 40°C until having a final volume of ca. 50 mL. The resulting suspension was cooled to 5 to 10°C in ca. 1 h. n-Hexane (252 ml) was added in the process of the cooling. After stirring for another 2 h the solid was filtered off under Nitrogen. The filtrate was washed with n-Hexane (2 times with 32mL each). 29.1 g of compound of formula (I-down) (118 mmol) were obtained based on LOD-method.Yield: 89% yieldPurity: 99.2%.Enantiomeric purity: 0.5 area% (R)-enantiomer (HPLC, method 2) |
91% | With dmap; thionyl chloride In benzene for 3h; Reflux; | General method for the synthesis of acid chloride General procedure: To a solution of 1.2 Molar equivalents of NSAID’s in drybenzene, thionyl chloride (1 ml) and dimethyl-amino-pyridine(1 mg) were added. Then, the reaction mixture wasrefluxed for 2-3 h. After completion of refluxing, thionylchloride along with benzene was evaporated. |
89% | With thionyl chloride; N,N-dimethyl-formamide In chloroform 1.) reflux, 2 h, 2.) r.t., 18 h; | |
89% | With thionyl chloride In cyclohexane at 60℃; for 2h; | 8 Example 8; Preparation of (5) -2- ( 6-Methoxy-2-naphtyl) propionyl chloride (compound Va' ); (S) -Naproxen (compound Ia, 56 kg, 243 mol) and cyclohexane (420 L) and triethylamine (51 g, 0.50 mol) were added to a 800 L reaction vessel and the resulting suspension was stirred under nitrogen and heated to an inner temperature of 600C. After this a parallel addition of thionyl chloride (34.7 kg, 292 mol) and a solution of triethylamine (76 g, 0.75 mol) in cyclohexane (14 L) was started and continued over 1.5 h. The solution of triethylamine was added under the liquid surface of the suspension. After the addition was finished the reaction mixture was agitated for another 30 min at an inner temperature of 600C after which HPLC showed full conversion. The reaction solution was filtered hot and then cooled slowly to 00C. Crystallisation started at around 500C and after reaching 00C the slurry was stirred for another 30 min before the crystals were filtered off using a pressure filter. The crystals were washed with cyclohexane (75 L) and then dried under vacuum at 400C to give 54 kg (89%) of pure Via as white crystals. |
88.8% | With thionyl chloride; N,N-dimethyl-formamide In chloroform for 3h; Heating / reflux; | 30 Compound 2: Compound 2 was prepared from the corresponding carboxylic acid. Thionyl chloride (1.24 g, 10.42 mmoles) was added to a solution of (S)-(+)-2-(6- methoxy-naphthalen-2-yl)-propionic acid (Naproxen, 2 g, 8.69 mmoles) in 8.2 mL chloroform in a round bottom flask equipped with magnetic stirring. A drop of DMF was added and the mixture was refluxed for 3 hours. Chloroform and excess thionyl chloride were distilled from the reaction mixture while methylene chloride was added. Evaporation of residual solvent yielded fSj-2-(6-methoxy-naphthalen-2-yl)-propionyl chloride (1.918 g, 88.8 % yield). Rf = 0.2 (1 :1 hexanesrethyl ether). 1H NMR (400 MHz, CDCl3.) δ 9.98 (br, IH), 7.78 (t, 2H), 7.36 (d, IH), 7.18 (d, IH), 7.14 (m, 2H), 4.25 (q, IH), 3.93 (s, 3H), 1.68 (d, 3H). |
75% | With trichlorophosphate In m-xylene for 3h; Reflux; | |
53% | With oxalyl dichloride In toluene at 90℃; for 4h; | |
With thionyl chloride In toluene for 1h; Heating; | ||
With oxalyl dichloride; N,N-dimethyl-formamide In benzene at 45℃; for 1h; | ||
With thionyl chloride In benzene for 1.5h; Heating; | ||
With oxallyl chloride; N,N-dimethyl-formamide In dichloromethane | ||
With thionyl chloride In chloroform Heating; | ||
With oxalyl dichloride In dichloromethane at 0 - 20℃; for 3.5h; | ||
With oxalyl dichloride | ||
With thionyl chloride In toluene for 3h; Heating; | ||
With thionyl chloride In benzene Heating; | ||
With thionyl chloride In benzene a) reflux, 30 min, b) 20 deg C, 12 h; | ||
With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane for 8h; Ambient temperature; | ||
With oxalyl dichloride In N,N-dimethyl-formamide; benzene for 1h; Ambient temperature; | ||
With oxalyl dichloride at 20℃; for 1h; | ||
With thionyl chloride | ||
With thionyl chloride In toluene at 80℃; for 2h; | ||
With oxalyl dichloride In chloroform at 0 - 20℃; for 1.5h; | 91 This prodrug was synthesized as shown in Scheme 11, Method E. Thus, to a solution of naproxen (1.698 g, 7.37 mmol) in chloroform (20 mL) at 0-5° C. was added oxalyl chloride (0.8 mL, 8.844 mmol), followed by 2-3 drops of DMF. The mixture was stirred at RT for 90 min and concentrated. This acid chloride (7.37 mmol) was treated with LI-5.TFA (6.7 mmol) in THF (20 mL) and cooled to 0° C. To this was added TEA (5.6 mL, 40 mmol) and stirred at RT for 3 h. The mixture was concentrated and the residue, after usual aqueous work-up and chromatographic purification, afforded 0.409 g (14%) of pure I-C1-NOPD12. 1H-NMR (CDCl3, 300 MHz): δ 1.24 (d, 3H), 2.87 (t, 2H, J=6.5 Hz), 2.93 (t, 2H, J=6.7 Hz), 3.64 (q, 2H, 7.5 Hz), 3.76 (m, 1H), 3.88 (s, 3H), 4.70 (t, 2H, J=6.6 Hz), 4.79 (br s, 1H), 6.97-7.08 (m, 3H), 7.35-7.46 (m, 3H). | |
With thionyl chloride In dichloromethane for 2h; Heating; | ||
With oxalyl dichloride at 20℃; for 1h; | 14 (S)-naproxen (5.5g, 0.024mol) and oxalyl chloride (18ml) were added to a reaction flask and reacted at room temperature for 1 hour. The excessive oxalyl chloride was evaporated under reduced pressure to give (S)-6-methoxy-2-naphthyl isopropionyl chloride. | |
With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 1h; Inert atmosphere; | ||
With thionyl chloride at 80℃; for 1h; | ||
With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 3.16h; Inert atmosphere; | 3.1 DMF (~3-4 drops) followed by oxalyl chloride (11.0 mL, 130.4 mmol) were added drop-wise to a stirred solution of naproxen (DC1, 25.0 g, 108.7 mmol) in 200 mL of DCM at RT under a nitrogen atmosphere over 10 minutes. The mixture was stirred at RT under nitrogen atmosphere for 3 h. The mixture was concentrated in vacuo to afford crude naproxen acid chloride as a yellow solid, which was used as such in the next step. Yield: 27.0 g (quantitative). | |
With oxalyl dichloride for 0.5h; | ||
With thionyl chloride In benzene for 3h; Reflux; | ||
With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane for 1.5h; Cooling with ice; | ||
With oxalyl dichloride In dichloromethane at 0 - 20℃; | ||
With oxalyl dichloride In dichloromethane; N,N-dimethyl-formamide at 25℃; for 12h; | ||
With oxalyl dichloride In hexane for 2h; Reflux; Inert atmosphere; | ||
With oxalyl dichloride; N,N-dimethyl-formamide In 1,2-dichloro-ethane for 1h; Reflux; | General procedure forthe synthesis of compounds 18a-b and 18f General procedure: Oxalyl chloride (1.50 mmol) was addedto a solution of Drug-1 (1.00 mmol) in DCE (5 mL), followed by the addition of1-2 drops of DMF. The reaction mixture was refluxed for 1 h and concentrated.The residue was taken up in CH2Cl2 (5 mL), to which wasadded a solution of 11 (2.00 mmol)and Et3N (3.00 mmol) in CH2Cl2 (10 mL) at 0 oC.After stirring for 8 h, the reaction mixture was concentrated. The residue waspartitioned between EtOAc (30 mL) and 0.5 N HCl (10 mL). The organic layer waswashed with brine (10 mL), dried (Na2SO4), concentratedand purified by silica gel column chromatography to afford the title compounds. | |
With oxalyl dichloride | ||
With thionyl chloride; triethylamine In toluene at 40℃; for 4h; | ||
In dichloromethane; N,N-dimethyl-formamide at 0℃; Reflux; | ||
With thionyl chloride In benzene for 2h; Inert atmosphere; Reflux; | ||
With oxalyl dichloride In dichloromethane; N,N-dimethyl-formamide at 0℃; for 3h; | ||
With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 0 - 20℃; for 2.5h; Inert atmosphere; | Steps 1 and 2: Synthesis of (2S)-1-chloroethyl 2-(6-methoxynaphthalen-2-yl)propanoate (D2-2a) To a stirred solution of naproxen (D2-C(=O)OH, 5.0 g, 21.71 mmol) in dichloromethane (50 mL) at 0°C under nitrogen was added oxalyl chloride (5.51 mL, 65.14 mmol) followed by catalytic amount of dry DMF (2 drops) and the mixture was then stirred at room temperature for 2.5 h and concentrated. Intermediate naproxen acid chloride D2-1 was taken in dichloromethane (30 mL), added zinc chloride (0.06 g, 0.43 mmol) as a solid and stirred vigorously at room temperature for 15 min. Reaction flask was then cooled at -15 °C and a solution of acetaldehyde (Aa, 1.22 mL, 21.71 mmol) in dichloromethane (20 mL) was added drop wise. After 25 min of stirring, cooling bath was removed and continued stirring at room temperature for 12 h. Reaction mixture was diluted with dichloromethane (30 mL) and washed with water (50 mL), saturated NaHCO3 solution (50 mL) and brine (50 mL). Organic layer was dried over MgSO4 and concentrated. Crude compound was purified by silica gel (200-400 mesh) column chromatography using 5 % EtOAc / Pet. ether to give the corresponding chloro intermediate D2-2a (5.10 g, 80.0 %) as yellow oil. | |
With thionyl chloride at 85℃; for 3h; | ||
With thionyl chloride In dichloromethane; N,N-dimethyl-formamide at 20℃; for 3h; Inert atmosphere; | ||
With thionyl chloride In benzene Reflux; | ||
With oxalyl dichloride In hexane for 2h; Reflux; Inert atmosphere; enantioselective reaction; | ||
With oxalyl dichloride In dichloromethane; N,N-dimethyl-formamide at 0 - 20℃; for 2.5h; Inert atmosphere; | 3.7. Synthesis of (S)-Naproxen Acyl Chloride 9 To a solution of (S)-Naproxen (2.5 eq.) in anhydrous CH2Cl2 (15 mL) and N,N-dimethylformamide (one drop), oxalyl chloride (3 eq.) at 0 C was added. The reaction mixture was stirredat room temperature for 2.5 h under a nitrogen atmosphere, and after this time, the solvent andresidual oxalyl chloride were removed under reduced pressure to continue the reaction, obtainingthe (S)-Naproxen acyl chloride 9, which was not isolated and used immediately in the next reaction. | |
With oxalyl dichloride In dichloromethane at 25℃; | ||
With bis-(2-oxo-3-oxazolidinyl)phosphoryl chloride In dichloromethane | ||
With thionyl chloride In toluene at 110℃; for 5h; | ||
With thionyl chloride In dichloromethane Reflux; | ||
With thionyl chloride In dichloromethane for 5h; Heating / reflux; | 1 A solution of naproxen (1.38 g, 6 mmol) and thionyl chloride (1.06 g, 9 mmol) in 100 mL of methylene chloride was refluxed for 5 hours, before the removal of the solvent under vacuo.Without further purification, the residue was dissolved in 5 mL of methylene chloride, and this solution was added dropwise to a mixture of imidazole (0.41 g, 6 mmol) and triethylamine (1.7 mL, 12 mmol) in 20 mL of methylene chloride. After the mixture was allowed to stir for additional 4 hours, the solvent was removed, and the crude residue was purified on a silica gel column, eluting with 30% ethyl acetate in hexane. The desired product was obtained 1.5 g (90% yield) as an oil first, which was then triturated with ether/hexane to give a white solid. 1H NMR (DMSO-d6, 300 MHz): δ 1.57 (d, J = 6 Hz, 3H); 3.86 (s, 3H); 4.88 (dd, J = 6 Hz, IH); 7.01 (s, IH); 7.15 (dd, J = 3 Hz, IH); 7.29 (s, IH); 7.48 (dd, J = 3 Hz, IH); 7.75 (t, J = 3 Hz, IH); 7.79 (d, J = 3 Hz5 IH); 7.82 (d, J = 3 Hz, IH); 7.88 (s, IH); 8.54 (s, 1H).8.25 (s, IH); 7.52 (s, IH); 7.14 (s, IH); 5.13 (dd, J=4.0 and 9.2 Hz, IH); 3.77- 3.55 (m, 2H); 2.53-2.34 (m, IH); 2.20-2.01 (m, 3H); 1.92-1.61 (m, 2H), 1.23 (s, 6H), 0.88 (t, J=7.6 Hz, 3H). Anal. Calcd. for C17H16N2O2: C, 72.8; H, 5.8; N, 10.0. Found: C, 72.5; H, 5.8; N5 9.9. TLC: Rf = 0.3 (60% EtOAc/hexane). | |
With thionyl chloride Heating; | ||
With oxalyl dichloride; N,N-dimethyl-formamide In dichloromethane at 20℃; for 5h; | ||
With oxalyl dichloride In dichloromethane; N,N-dimethyl-formamide at 20℃; for 1h; | ||
With oxalyl dichloride In benzene at 20℃; for 6h; | ||
With thionyl chloride; N,N-dimethyl-formamide for 3h; Reflux; | Procedure for synthesis of compound 3af 0.5 mmol of Naproxen was added into a solution of 2 mL of SOCl2 and a drop of DMF, the mixture was refluxed for 3 h with a drying tube. After completion, the excess SOCl2 was removed under vacuum to give compound 4, which can be used directly in the next step. In an undivided three-necked flask (25 mL) equipped with a stir bar, 6-aminouracil (0.5 mmol, 63.6 mg), diphenyldiselenides (0.25 mmol, 78.1 mg), KI (0.125 mmol, 20.1 mg) and DMSO (8 mL) were added. The flask was equipped with platinum electrodes (15 mm x 15 mm x 0.3 mm) as cathode, graphite rod (Φ 6 mm) as the anode. The reaction mixture was stirred and electrolyzed at a constant current of 10 mA under room temperature for 15 h. The compound 4 above and NEt3 (3.0 equiv., 1.5 mmol) were added into the reaction mixture at 0 °C, then stirred at rt for another 8 h. After completion, the reaction mixture was diluted by ice water (10 mL), and the product was extracted with ethyl acetate (3 × 20 mL). The organic layer was dried over anhydrous Na2SO4 and concentrated under reduced pressure. The pure products 3af was obtained by flash chromatography on silica gel (elute: dichloromethane/ethylacetate = 3 : 1) . |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With ammonium acetate;Resolution of racemate;Purification / work up; | Enantiomers of test racemates TR 19-23, of known drugs from the non-steroidal antiinflammatory group, were separated on analytical HPLC columns (250 mm x 4,6 mm), filled with CSP-4 or CSP-3. Since these compounds are structurally free carboxyl acids, it was necessary to use a polar mobile phase containing a certain amount of ammonium acetate. Results obtained by the enantioselective separation of these compounds are shown in Table 5 and the chromatogram achieved for the enantiomers of naproxen is shown in Figure 8. <n="20"/>TABLE 5 Enantiomer separations for test racemate TR 20-23 on the column filled withCSP-3 (250 mm x 4.6 mm ID), with hexane : 2-PrOH = 8:2 + lg/L NH4OAc as the mobile phase, 1 ml/min, 254 nm. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
31% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; triethylamine; In N,N-dimethyl-formamide; at 20℃; | 39a. 2-(4-(2-Hydroxyethoxy)phenoxy)ethyl (2S)-2-(6-methoxy(2-naphthyl))propanoate A solution of (2S)-2-(6-methoxy(2-naphthyl))propanoic acid (naproxen, 4.27 g, 18.5 mmol), hydroquinone bis(2-hydroxyethyl) ether (10.6 g, 53.3 mmol), N,N-dimethylaminopyridine (DMAP, 2.71 g, 22.2 mmol), 1-(3-dimethylaminopropyl)-3-ethylcarbodiimide hydrochloride (9.34 g, 48.7 mmol) and NEt3 (13 mL, 93.3 mmol) in DMF (100 mL) was stirred at ambient temperature overnight. The reaction mixture was evaporated to dryness under vacuum and the residue was partitioned between HCl (3N, 100 mL) and CH2Cl2 (200 mL). The organic layer was washed with water, brine, dried over Na2SO4, filtered and concentrated. The product was separated by silica gel column chromatography eluding with EtOAc/hexane (1:1, Rf=0.15) and then recrystallized from ethyl ether and hexane to give the title compound as a white solid (6.01 g, 31% yield). Mp 76-78 C. 1H NMR (CDCl3) delta 7.7-7.64 (m, 3H), 7.42-7.38 (m, 1H), 7.15-7.08 (m, 2H), 6.74-6.72 (m 4H), 4.45-4.36 (m, 2H), 4.1-3.85 (m, 7H), 3.90 (s, 3H), 2.13 (br. t, 1H), 1.58 (d, J=7.2 Hz, 3H). 13C NMR (CDCl3) delta 174.6, 157.5, 153.0, 152.8, 135.4, 133.6, 129.2, 128.8, 127.1, 126.1, 125.9, 118.8, 115.7, 115.3, 105.5, 69.7, 66.6, 63.1, 61.4, 55.2, 45.2, 18.4. MS(API) m/z 428 (M+NH4)+. Anal. calcd. for C24H26O6: C, 70.23; H, 6.38. Found: C, 70.01; H, 6.39. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With dmap; dicyclohexyl-carbodiimide In dichloromethane at 20℃; | 44.a 44a. (2R)-27hydroxy-3-(phenylmethoxy)propyl (2S)-2-(6-methoxy(2-naphthyl))propanoate [0593] A solution of (2S)-2-(6-methoxy(2-naphthyl))propanoic acid (naproxen, 3.70 g, 16.1 mmol), (R)-(+)-3-benzyloxy-1,2-propanediol (2.92 g, 19.0 mmol), N,N-dimethylaminopyridine (DMAP, 0.40 g, 3.3 mmol) and 1,3-dicyclohexylcarbodiimide (3.61 g, 17.5 mmol) in CH2Cl2 (120 mL) was stirred at ambient temperature overnight. The byproduct, dicyclohexyl urea, was removed by filtration. The reaction mixture was partitioned between HCl (3N, 50 mL) and CH2Cl2 (50 mLx2). The combined organic extracts were back washed with water, brine, dried over Na2SO4, filtered, concentrated and dried under vacuum. The product was separated by silica gel column chromatography eluting with EtOAc:hexane (1:2, Rf=0.23) to give a mixture of the 1- and 2-glycerol ester isomers (88:12, 3.87 g). 1H NMR (300 M CDCl3) ? 7.69-7.64 (m, 3H), 7.40-7.03 (m, 8H), 5.34 (s, 2H), 4.17-4.14 (m, 2H), 3.88 (s, 3H), 3.9-3.85 (m, 2H), 3.33-3.28 (m, 2H), 2.45 (br. d, 1H), 1.56 (d, J=7.2 Hz, 3H). 13C NMR (75 MHz, CDCl3) ? 174.6, 157.6, 137.6, 135.4, 133.6, 129.6, 129.2, 128.8, 128.3, 127.7, 127.61, 127.55, 127.1, 126.1, 125.9, 119.0, 105.5, 73.3, 70.6, 68.8, 65.5, 62.2, 55.2, 45.3, 18.3. Mass spectrum (API-TIS) m/z 412 (M+NH4)+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
74% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 0 - 20℃; for 72.0h; | 29c. tert-Butyl 2-((2S)-2-(6-methoxy(2-naphthyl))propanoylaminooxy)acetate A mixture of (2S)-2-(6-methoxy(2-naphthyl))propanoic acid (naproxen, 1.6 g, 7.0 mmol), the product of Example 29b (1 g, 7.0 mmol) and N,N-dimethylaminopyridine ((DMAP, 0.85 g, 7.0 mmol) in CH2Cl2 (20 mL) at 0 C. was treated with 1-(3-(dimethylamino)propyl)-3-ethylcarbodimide hydrochloride (1.34 g, 7.0 mmol). The reaction mixture was stirred at room temperature for 3 days, diluted with CH2Cl2, washed with water, brine and dried over Na2SO4. The residue after filtration and evaporation was chromatographed on silica gel eluding with EtOAc:hexane (1:3 to 1:2) to give the title compound (1.9 g, 74% yield) as a white solid. Mp 82-84 C. 1H NMR (300 MHz, CDCl3) δ 8.72-8.85 (bs, 1H), 7.63-7.70 (m, 3H), 7.34 (dd, J=1.6 and 8.5 Hz, 1H), 7.02-7.16 (m, 2H), 4.15-4.37 (bs, 2H), 3.89 (s, 3H), 3.49-3.64 (bs, 1H), 1.56 (d, J=7.0 Hz, 3H), 1.30 (s, 9H). 13C NMR (75 MHz, CDCl3) δ 171.9, 168.8, 157.8, 135.4, 133.8, 129.3, 129.0, 127.5, 126.0, 119.2, 105.6, 82.7, 72.5, 55.3, 44.0, 27.9, 18.3. Mass spectrum (API-TIS) m/z 360 (MH+). Anal. calcd. for C20H25NO5: C, 66.84; H, 7.01; N, 3.90. Found: C, 66.85; H, 6.99; N, 3.84. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
98% | With hydrogenchloride; In methanol; at 20℃; | Naproxen, (2) was prepared by treating equimolar amount of Naproxen-Na, (1) and HCl.Yield: 98%, mp. 152 C. nucm-1: (C=O) 1718 cm-1, (CO) 1174 cm-1; (OH) 3186 cm-1,(ArOCH3) 1265 cm-1. C14H14O3 (230.3): calcd. C, 73.03; H, 6.13; O, 20.85; found C, 72.93; H, 6.03. |
94.3% | With hydrogenchloride; In water;pH < 2;Inert atmosphere; | (S)-naproxen (S1). With a ceramic mortar and pestle, 150 generic naproxen sodium pills (220 mg/ea, 33.0 g, 131 mmol) were ground to a ne powder. The resulting light blue powder was suspended in 750 mL of methanol, stirred vigorously for 1 hour, then ltered through CeliteR 545 and concentrated in vacuo to aord naproxen sodium as a white solid. The crude naproxen sodium was dissolved in 1000 mL of H2Othen 500 mL of CH2Cl2 was added. With stirring, concentrated HCl was added slowly until the aqueous solution pH was < 2. The product was extracted with CH2Cl2 (3 x 500 mL), dried over anhydrous MgSO4,ltered, and concentrated to aord pure (S)-naproxen as a white solid (28.4 g, 94.3%). Characterization data were in agreement with the literature values. |
B. Naproxen 500 mg of naproxen sodium are compacted as granules with povidone k-29/32, 23.6 mg; microcrystalline cellulose, NF, 105.9 mg; croscarmellose sodium, NF, 13.5; talc, 27 mg; magnesium stearate, 5 mg. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
In methanol; | EXAMPLE 26 This example illustrates the conversion of free carboxylic acid of Example 1-25 to various salts. To a solution of 300 mg of (S)-2-(6-methoxy-2-naphthyl)-propionic acid in 5 ml of methanol is added a 1 molar equivalent of sodium hydroxide, in the form of a 0.1N solution. The solvent is evaporated in vacuo and the residue is taken up in 2 ml of methanol, followed by precipitation with ether, to yield crude sodium (S)-2-(6-methoxy-2-naphthyl)propionate. Likewise, other salts, e.g., ammonium and potassium (S)-2-(6-methoxy-2-naphthyl)propionate, are prepared by substituting ammonium hydroxide and potassium hydroxide for sodium hydroxide. | |
With sodium hydroxide; In methanol; | EXAMPLE 10 A mixture prepared by adding 23 g of d-2-(6-methoxy-2-naphthyl)propionic acid as prepared in Example 9 to 4 g of sodium hydroxide in 500 ml of aqueous methanol was stirred for 3 hours at room temperature. Then the mixture was evaporated to yield sodium d-2-(6-methoxy-2-naphthyl)propionate. THe product was replaced into toluene then isolated by centrifugation and washed with hexane prior to drying. The product melts at about 255 C. with decomposition and its infrared spectrum exhibits maxima at 1260, 1600, 1625 and 1725 cm-1. The yield was 95% based on d-2-(6-methoxy-2-naphthyl)propionic acid. | |
With sodium hydroxide; In methanol; at 55℃;Industry scale; | Methanol (2630 L) and sodium hydroxide (86 kg) are charged into a reactor and stirred for 15-30 minutes. Naproxen (500 kg) is added and the mixture is heated to 55+/-5C and maintained for 15-30 minutes. Carbon (10 kg) is added and the mass is stirred for 15-30 minutes, then the mass is cooled to below 400C. The mass is filtered and the filter washed with methanol (140 L), then the solvent from the filtrate is evaporated under reduced pressure at 50+100C to 50-60% of the initial volume. The mass is cooled to 7.5+/-7.5C and isopropyl alcohol (2500 L) is added over 150+60 minutes. The mass is cooled to 5+5C and maintained for 45- 60 minutes. The formed solid is filtered and washed with isopropyl alcohol (100 liters) and dried at 65+5C to afford 450 kg of the title compound. |
With sodium hydroxide; In water;Schlenk technique; Inert atmosphere; | Sodium naproxenate (NaL2) was prepared from neutralization reaction of HL2 with NaOH at 1:1 molar ratio in aqueous solution under stirring. When the pH reached about 7.0 (neutral), the solution was filtered and then roto-evaporated to dryness. The solid was washed with CH2Cl2 and dried under vacuum. 1H NMR, 300 MHz, d-methanol, delta (ppm vs TMS): 7.70-7.65 (m, 3H, CHring 3,4,7); 7.50 (dd, 3JH-H = 8.5, 4JH-H = 1.8 Hz, 1H, CHring 8); 7.16 (dd, 4JH-H = 2.6 Hz, 1H, CHring 6); 7.06 (dd, 3JH-H = 8.9, 4JH-H = 2.6 Hz, 1H), CHring 5); 3.87 (s, 3H, O-CH3 9); 3.71 (q, 3JH-H = 7.1 Hz, 1H, CHchiral 1); 1.49 (d, 3JH-H = 7.1 Hz, 3H, Cchiral-CH3 2). ATR-FTIR salt major bands, (cm-1): 1630w, 1605m (CCring + in plane CHring bending); 1546s (aCOO); 1437s (sCOO); 1389 vs (CH3 rocking); 1263m (in plane CCring + in plane CHring deformation + in plane CH bending); 1213s (C-O, in3plane CCring + CHring deformation + in plane CH bending ); 1163m (C-O + C-C + in plane CH bending + CH3); 1026s (C-O + CH3 rocking). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
at 60 - 70℃; | EXAMPLE 10; Preparation of Various Complexes Comprising Brimonidine and Selected CounterionsIn this experiment, various complexes comprising Brimonidine and counterions of one of the following acids were prepared: pamoic acid, capric acid, sebacic acid, hippuric acid, naproxen, 1-hydroxy-2-naphthoic acid, palmitic acid, and stearic acid. Variations of the procedure described in the following disclosure may be made within the skill of a person of ordinary skill in the art without departing from the scope of the present invention. Brimonidine free base in a preselected solvent was heated to about 60-70 C. The organic acid in another portion of the solvent was added into the heated mixture or was included in the original mixture before heating. The heating of the combined mixture was continued for an additional period, which was not critical. In certain embodiments, an antisolvent was added to the combined mixture, preferably at a lower temperature, to effect a precipitation of the complex of brimonidine and the counterion. It may be advantageous to remove a portion of the solvent and antisolvent to assist the precipitation. In certain other embodiments, the heated combined mixture was cooled down to a lower temperature, such as room temperature (or below) to effect the precipitation of the complex of brimonidine and the counterion. The precipitate was then filtered and dried to yield the final complex. The solubility of various complexes in water at the resulting pH is shown in Table 9. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With benzoic acid anhydride; N-ethyl-N,N-diisopropylamine;(R)-(+)-2-phenyl-2,3-dihydrobenzo[d]imidazo[2,1-b]thiazole; In dichloromethane; at 20℃; for 6h;Resolution of racemate;Product distribution / selectivity; | Experimental Example 8Production of Optically Active Ester and Optically Active Carboxylic Acid Using Naproxen (Optical Resolution of Naproxen) As shown by the above reaction equation, an optically active ester and optically active carboxylic acid are obtained by reacting 1,1-di(1-naphthyl)methanol or 1,1-di(9-phenanthryl)methanol and racemic naproxen. The results are shown in Table 8.; Entry 53(R)-naproxen di(1-naphthyl)methylesterHPLC (CHIRALPAK AD-H, i-PrOH/hexane=1/9, flow rate=1.0 mL/ml): tR=13.7 min (10.6%), tR=17.4 min (89.4%);IR (neat): 3034, 1733, 1604, 1508, 782, 679 cm-1;1H NMR (CDCl3): delta8.29 (s, 1H, 1'-H), 8.00-7.90 (m, 1H, Ph), 7.82-6.96 (m, 17H, Ph), 6.95-6.81 (m, 2H, Ph), 3.86 (q, J=7.0 Hz, 1H, 2-H), 3.79 (s, 3H, OMe), 1.49 (d, J=7.0 Hz, 3H, 3-H);13C NMR (CDCl3): delta173.6, 157.6, 135.1, 134.7, 134.5, 133.8, 133.7, 133.6, 131.2, 130.8, 129.3, 129.1, 128.9, 128.8, 128.7, 128.6, 128.3, 127.1, 126.7, 126.5, 126.3, 126.2, 125.8, 125.6, 125.3, 125.2, 125.0, 123.4, 123.3, 118.9, 105.5, 71.2, 55.2, 45.5, 18.3;HR MS: calculated for C35H28O3Na (M+Na+)=519.1931; found 519.1932. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With benzoic acid anhydride; N-ethyl-N,N-diisopropylamine;(R)-(+)-2-phenyl-2,3-dihydrobenzo[d]imidazo[2,1-b]thiazole; In dichloromethane; at 20℃; for 6h;Resolution of racemate;Product distribution / selectivity; | Entry 55To a dichloromethane solution (2.0 mL) containing benzoic anhydride (54.3 mg, 0.240 mmol) and racemic naproxen (46.1 mg, 0.200 mmol); diisopropylethylamine (62.7 muL, 0.360 mmol), benzotetramisole (2.5 mg, 0.010 mmol), and 1,1-di(9-phenanthryl)methanol (38.4 mg, 0.100 mmol) were added in order at room temperature. After stirring the reaction mixture solution at room temperature for 6 hr, the reaction was stopped with saturated ammonium chloride water. After fractionating the organic layer, the aqueous layer was extracted 4 times with dichloromethane. After combining the organic layers, they were dried with anhydrous sodium sulfate. After filtering the solution, it was vacuum concentrated, and the obtained mixture was fractionated by thin layer silica gel chromatography to obtain the corresponding optically active naproxen ester (59.7 mg, 50%, 88% ee) and the unreacted optically active naproxen (12.6 mg, 27%, 61% ee).(R)-naproxen di(9-phenanthryl)methylesterHPLC (CHIRALCELL OD-H, i-PrOH/hexane=1/4, flow rate=0.75 mL/mi): tR=23.7 min (94.1%), tR=41.1 min (5.9%);IR (KBr): 3063, 1731, 1605, 1265, 1028, 749, 727 cm-1;1H NMR (CDCl3): delta8.84-8.50 (m, 4H, Ph), 8.43 (s, 1H, 1'-H), 8.25-8.12 (m, 1H, Ph), 7.80-7.08 (m, 18H, Ph), 6.83-6.75 (m, 1H, Ph), 4.03 (q, J=7.1 Hz, 1H, 2-H), 3.96 (s, 3H, OMe), 1.64 (d, J=7.1 Hz, 3H, 3-H);13C NMR (CDCl3): delta173.5, 157.9, 135.2, 134.0, 132.9, 132.6, 131.0, 130.9, 130.6, 130.6, 130.3, 130.2, 129.8, 129.5, 129.1, 129.0, 128.9, 128.3, 128.0, 127.4, 127.3, 127.2, 126.8, 126.6, 126.6, 126.5, 126.4, 126.3, 126.2, 124.2, 123.9, 123.4, 123.1, 122.4, 122.2, 119.0, 105.6, 71.0, 55.4, 45.7, 18.0.(S)-naproxenHPLC (CHIRALPAK AD-H, i-PrOH/hexane/TFA=1/10/0.01, flow rate=1.0 mL/min); tR=13.8 min (18.9%), tR=15.8 min (81.1%);1H NMR (CDCl3): delta9.42 (br s, 1H, COOH), 7.68-7.55 (m, 3H, Ph), 7.33-7.28 (m, 1H, Ph), 7.13-6.99 (m, 2H, Ph), 3.83 (s, 3H, OMe), 3.79 (q, J=7.2 Hz, 1H, 2-H), 1.50 (d, J=7.2 Hz, 3H, 3-H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
72.14% | The ester 3a was prepared according to reported procedure from the literature (Org. Syn., 1984, 63, 183). Naproxen (1a 10.00 g, 43.427 mmol, purchased from Aldrich) and 4-(Dimethylamino)pyridine (DMAP, 0.53 g, 4.338 mmol, purchased from Aldrich) were dissolved in anhydrous N,N-dimethylformamide (DMF) and 1,3-diisopropylcarbodiimide (DICC, 6.8 mL, 43.914 mmol, purchased from Aldrich) was added into the solution and stirred at ambient temperature for 5 minute. 6-aminohexanoic acid methyl ester hydrochloride (2, 10.00 g, 57.408 mmol, purchased from Fluka) and diisopropylethylamine (DIEA, 10 mL, purchased from Aldrich) were added into the stirring solution after 5 minute of addition of DICC and stirred overnight at ambient temperature. DMF was removed from the reaction in vacuo, the product was extracted into ethyl acetate (EtOAc, 200 mL), washed successively with aqueous KHSO4, water, sodium bicarbonate solution and water. The organic layer was dried over anhydrous sodium sulfate (Na2SO4) and filtered. A white solid was precipitated out from the EtOAc extract by adding hexane to afford the desired compound 3a, 11.20 g (72.14%). 1H NMR (400 MHz, [D6]DMSO, 25 C.): delta 7.95-7.92 (t, J(H,H)=5.2 & 5.6 Hz, 1H), 7.76-7.68 (m, 3H), 7.43-7,40 (dd, J'(H,H)=1.6 and J(H,H)=8.4 Hz, 1H), 7.25-7.24 (d, J(H,H)=2.0 Hz, 1H), 7.13-7.11 (dd, J'(H,H)=2.4 and J(H,H)=8.8 Hz, 1H), 3.84 (s, 3H), 3.70-3.65 (q, J(H,H)=6.8 and 7.2 Hz, 1H), 3.54 (s, 3H), 3.00-2.97 (q, J(H,H)=6.8 Hz, 2H), 2.21-2.17 (t, 2H), 1.48-1.29 (m, 7H), 1.19-1.13 (m, 2H). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
90%; 89% | In the same way as the 2-phenylpropanoic acid (S)-53, oxazolidin-2-one (S,R)-syn-9 (0.2 g, 0.53 mmol), lithium hydroxide monohydrate (45 mg, 1.06 mmol) and hydrogen peroxide (0.30 mL, 3.53 M in H2O, 1.06 mmol) in THF/water (1:1; 5 mL) gave, the recovered 4-phenyl-oxazolidin-2-one (R)-8 (77 mg, 89percent) as a white solid; and 2-(6-methoxynaphthalene-2-yl)propanoic acid (S)-59 (109 mg, 90percent) as a white solid; RF [diethyl ether] 0.56; mp 151-153 °C; inlMMLBox (c 4.2, CHCl3); numax (CHCl3)/cm-1 1710 (CO); deltaH (400 MHz; CDCl3) 7.70 (2H, dd, J 8.4 and 2.8, 2 .x. CH; Ph), 7.68 (1H, s, CH; Ph), 7.41 (1H, dd, J 8.4 and 1.8, CH; Ar), 7.16-7.10 (2H, m, 2 .x. CH; Ph), 3.91 (3H, s, CH3O), 3.88 (1H, q, J 7.0, ArCHCH3) and 1.59 (3H, d, J 7.0, ArCHCH3); deltaC (100 MHz; CDCl3) 180.2 (CO), 157.9 (i-CO; Ar), 134.8, 133.8 and 128.9 (3 .x. i-C; Ar), 129.3, 127.2, 126.2, 126.1, 119.0 and 105.6 (6 *.x. CH; Ar), 55.3 (CH3O), 45.2 (ArCHCH3) and 18.1 (ArCHCH3); m/z 230 (60percent, M+) and 185 (100, ArCHCH3) (Found M+, 230.0906; C14H14O3 requires 230.0904). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With benzotriazol-1-ol; dicyclohexyl-carbodiimide; In dichloromethane; at 30℃;Product distribution / selectivity; | Racemic (+/-)-10, 11 -dihydro-10-hydroxy-5H- dibenz[b,f]azepine-5-carboxamide (100 g), dichloromethane (500 mL) and naproxen (108.69 g) are charged into a round-bottom flask and stirred for 5 minutes. Dicyclohexylcarbodiimide ("DCC", 105.7 g) and 1-hydroxybenzotriazole (OmicronBetaTau, 5.5 g) are added to the mixture. The reaction mixture is maintained at 30C for 7-8 hours, then filtered and the solid washed with dichloromethane (300 mL). The filtrate is evaporated completely under reduced pressure. Ethyl acetate (1800 mL) is added to the mass and stirred at 29C for 15-20 minutes. The mixture is heated to reflux temperature and maintained for 50-60 minutes. The solid obtained is collected by filtration, washed with ethyl acetate (360 mL) and dried at 70C to afford 24.9 g of naproxen ester of (S)-(+)-10, 1 1-dihydro-10- hydroxy-5H-dibenz[b,f]azepine-5-carboxamide. Purity by HPLC: 91.8%; choral purity by HPLC: 93.9%. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
63.1% | With dmap; dicyclohexyl-carbodiimide In dichloromethane at 0℃; for 3h; | 1.1 Step 1: Preparation of (S)-2-((2-hydroxyethyl)disulfanyl)ethyl 2-(6-methoxy-naphthalen-2-yl) propanoate [NO-Naproxen (CD1-L1-OH)]; A solution of DCC (13.0 g, 62.6 mmol) in DCM (25 mL) was added drop-wise over 5 minutes to a stirred solution of naproxen (CD1, 12.0 g, 52.2 mmol), bis(2-hydroxyethyl) disulfide (HO-L1-OH, 13.4 g, 104.3 mmol) and DMAP (1.3 g, 10.4 mmol) in 250 mL of DCM at 0° C. and the mixture was stirred for 3 h when TLC analysis of the mixture indicated completion of the reaction. The mixture was filtered and the filtrate was washed with water (2×100 mL) and brine (1×100 mL). The organic layer was separated, dried over Na2SO4 and concentrated in vacuo to give the crude product which was purified by column chromatography (600 g of silica gel, 150-300 mesh). The expected bis-naproxen derivative (i.e., CD1-L1-CD1), which was formed as a minor undesired product, was eluted with 10% EtOAc in petroleum ether. The desired mono-acylated title compound, which was eluted with 20% EtOAc in petroleum ether, was obtained as a white solid. Yield: 12.0 g (63.1%); 1H NMR (CDCl3, 300 MHz): δ 1.58 (d, J=7.2 Hz, 3H), 2.77 (t, J=5.7 Hz, 2H), 2.86 (t, J=6.9 Hz, 2H), 3.77 (t, J=5.7 Hz, 2H), 3.87 (q, J=7.2 Hz, 1H), 3.91 (s, 3H), 4.28-4.42 (m, 2H), 7.08-7.17 (m, 2H), 7.40 (dd, J=8.4, 1.5 Hz, 1H), 7.64-7.73 (m, 3H); MS m/z: 384.1 [M+NH4]+. |
With dmap; diisopropyl-carbodiimide In dichloromethane at 0 - 20℃; for 12h; | 2.a Example 2. Synthesis of POSH-Naproxen Example 2. Synthesis of POSH-Naproxen Naproxen treated (5) with 2-hydroxyethyl disulfide (2) in the presence of DCC /DMAP in DCM undergoes mono esterification to yield compound 6. Compound 6 is further treated with diethyl chlorophosphate in the presence of triethyl amine and DMAP to yield POSH-Naproxen (7). Spectral data for compound 6 1H-NMR (500 MHz, CDC13): δ 1.33 (t, 6H, / = 7.0 Hz), 1.59 (d, 3H, J = 1.32 Hz), 2.87 (m, 4H), 3.76 (t, 2H, / = 6.6 Hz), 3.90 (s, 3H), 4.12 (m, 1H), 4.2-4.4 (m, 2H), 7.11 (m, 2H), 7.39 (m, 1H), 7.69 (m, 3H). EIMS: 367 (M++l), 389 (M++Na). Spectral data for compound 7 1H-NMR (500 MHz, CDC13): δ 1.57 (d, 3H, J = 1 Hz), 2.77 (t, 2H, / = 5.4 Hz), 2.87 (t, 2H, / = 5.4 Hz), 3.87 (m, 1H), 3.91 (s, 3H), 4.11 (m, 4H), 4.20 (m, 2H), 4.34 (m, 2H), 7.13 (m, 2H), 7.40 (dd, 1H, / = 8.31, 1.47 Hz), 7.66 (bs, 1H), 7.40 (d, 2H, / = 8.31, 1.47 Hz), 7.70 (d, 2H, J = 8.8 Hz). EIMS: 503 (M++l), 525 (M++Na). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With esterase from Sulfolobus tokodaii strain 7; In acetonitrile; at 70℃;pH 7;Enzymatic reaction; | General procedure: Two hundred microliters of 50 mM substrate (1a or 1b) solution in CH3CN was added to 4 ml of 400 mM HEPES-NaOH buffer (pH 7). To the resulting solution, 1 ml of Est007 solution (25 mug/ml) was added and the mixture was stirred for 48 h at 70 C. The reaction was stopped by addition of 2 ml of 2 M HCl. The products were extracted with 5 ml diisopropyl ether. The organic layer (4 ml) was concentrated in vacuo, and to this was added 400 mul diisopropyl ether, 100 mul methanol, and an excess amount of Me3SiMeN2 in hexane. The solution was vortexed and allowed to stand at room temperature for 30 min. Enatiomeric excess of methyl ester of 5a and 5b was determined by HPLC analysis using CHRALCEL OJ (Daicel Corporation, Japan). To determine the conversion rate, 500 mul of the reaction mixture was transferred to the tube, and the reaction was stopped by addition of 200 mul of CH3CN containing 2% CF3CO2H. The products were extracted with EtOAc which contains diethyl phthalate as an internal standard. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
84% | With O-(1H-benzotriazol-1-yl)-N,N,N',N'-tetramethyluronium hexafluorophosphate; N-ethyl-N,N-diisopropylamine; In N,N-dimethyl-formamide; at 20℃; for 14h;Inert atmosphere; | To a solution of naproxen (115 mg, 0.50 mmol) in anhydrous DMF (5 mL) was added the above-prepared compound (114 mg, 0.6 mmol), HBTU (247 mg, 0.65 mmol) and diisopropylethylamine (130 muL, 0.75 mmol). The mixture was stirred at room temperature under argon for 14 h, and then concentrated under reduced pressure. The residue was diluted with EtOAc and washed with 1 M HCl(aq), saturated NaHCO3(aq), and brine. The organic phase was dried over MgSO4, filtered, and purified by silica gel chromatography (EtOAc/hexane=1:9) to afford the desired product 60 (169 mg, 84%). C21H26N2O4S; colorless oil; 1H NMR (CDCl3, 400 MHz) delta 12.31 (0.55 H, s), 12.19 (0.45 H, s), 7.69 (3H, m), 7.38 (1H, br), 7.15-7.07 (2H, m), 4.02-3.90 (1H, br), 3.87 (3H, s), 2.30 (3H, s), 1.62 (3H, d, J=6.8 Hz), 1.37 (9H, br); HRMS (ESI) calcd for C21H27N2O4S: 403.1692, found: m/z 403.1700 [M+H]+. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
Diagram 2. Synthesis of Naproxen C0 (compound 9). Reactants and conditions: i/KMnO4 (2.0 equiv.), tBuOH/H2O (1/1), reflux, 4 hrs, then KMnO4 (2.0 equiv.), reflux, 16 hrs; ii/ MeOH, conc. H2SO4, reflux, 16 hrs; iii/ <strong>[39622-80-5]di<strong>[39622-80-5]methyl 2-bromoisophthalate</strong></strong> 6 (0.92 equiv.), Pd(PPh3)4 (0.03 equiv.), aq. Na2CO3 (4.2 equiv., 2 M), DME/EtOH, reflux, 16 hrs; iv/ aq. LiOH (7.2 equiv., 1 M), THF, reflux, 4 hrs. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
86% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride In dichloromethane at 0 - 20℃; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: The compounds were synthesized by solid phase peptide synthesis (SPPS) using 2-chlorotrityl chloride resin. The corresponding N-Fmoc protected amino acids with side chains properly protected, Fmoc-succinated cystamine, and <strong>[175281-76-2]4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)butanoic acid</strong> were used for SPPS. The first amino acidwas loaded on the resin at the C-terminal with the loading efficiency about 0.6 mmol/g. 20% piperidine in anhydrous N,N-dimethylformamide (DMF) was used during deprotection of Fmoc group. The next Fmoc-protected amino acid (3 equiv.) was then coupled to the free amino group using O-(Benzotriazol-1-yl)-N,N,N,N-tetramethyluroniumhexafluorophosphate (HBTU, 1 equiv.to Fmoc-AA) as the coupling reagent. The growth of the peptide chain was according to the established Fmoc SPPS protocol. After the last coupling step, excessive reagents were removed by a single DMF wash for 5minutes (5 mL per gram of resin), followed by five steps of washing using DCM for 1 min (5 mL per gram of resin). The peptide derivative was cleaved using 92.5% of trifluoroacetic acid with 2.5% of TMS, 2.5% of phenol,and 2.5% of H2O for 20 minutes. 20 mL per gram of resin of ice-cold diethylether was then added to cleavage reagent. The resulting precipitate was filtrated and washed by ice-cold diethylether. The resulting solid was purified by HPLC and dried by lyophilizer. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
General procedure: The compounds were synthesized by solid phase peptide synthesis (SPPS) using 2-chlorotrityl chloride resin. The corresponding N-Fmoc protected amino acids with side chains properly protected, Fmoc-succinated cystamine, and <strong>[175281-76-2]4-(4-(1-hydroxyethyl)-2-methoxy-5-nitrophenoxy)butanoic acid</strong> were used for SPPS. The first amino acidwas loaded on the resin at the C-terminal with the loading efficiency about 0.6 mmol/g. 20% piperidine in anhydrous N,N-dimethylformamide (DMF) was used during deprotection of Fmoc group. The next Fmoc-protected amino acid (3 equiv.) was then coupled to the free amino group using O-(Benzotriazol-1-yl)-N,N,N,N-tetramethyluroniumhexafluorophosphate (HBTU, 1 equiv.to Fmoc-AA) as the coupling reagent. The growth of the peptide chain was according to the established Fmoc SPPS protocol. After the last coupling step, excessive reagents were removed by a single DMF wash for 5minutes (5 mL per gram of resin), followed by five steps of washing using DCM for 1 min (5 mL per gram of resin). The peptide derivative was cleaved using 92.5% of trifluoroacetic acid with 2.5% of TMS, 2.5% of phenol,and 2.5% of H2O for 20 minutes. 20 mL per gram of resin of ice-cold diethylether was then added to cleavage reagent. The resulting precipitate was filtrated and washed by ice-cold diethylether. The resulting solid was purified by HPLC and dried by lyophilizer. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
68.3% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In tetrahydrofuran; at 20℃; for 22.5h;Cooling with ice; Inert atmosphere; | 2-(1H-benzo[d]imidazol-1-yl)ethyl 2-(6-methoxynaphthalen-2-yl)propanoate 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCl (EDC-HCl) (2.20 g, 11.5 mmol) was added solid all at once to a magnetically stirred solution of naproxen (2.30 g, 10.0 mmol), 1-(2-hydroxyethyl)imidazole (1.12 g, 10.0 mmol) and 4-Dimethylaminopyridine (61 mg, 0.5 mmol) in dry tetrahydrofuran (50 mL) cooled in an ice bath and kept under nitrogen. The reaction mixture was stirred in an ice bath for 30 min and at ambient temperature. More EDC-HCl (400 mg, 2 mmol) was added after 13 hrs, 17 hrs. After stirring for 22 hrs at room temperature the mixture was concentrated and the residue partitioned between water (50 mL), saturated NH4Cl (20 mL) and EtOAc (120 mL). The organic layer was washed with 50% saturated NH4Cl (2*50 mL), 50% saturated NaHCO3 (50 mL) and brine (50 mL). The organic layer was dried and concentrated. The oily residue was purified by Flash Chromatography using ethyl acetate and heptanes as eluent afforded a colourless oil (2.74 g, 84%) after drying in high vacuum. The oil was crystallised from ether and recrystallised from Tert-butylmethylether (?20 mL, seeded) to afford the title compound as a colourless solid (2.21 g, 68.3%). Mp. 60.6-61.3 C. 1H NMR (400 MHz, DMSO) delta 7.80 (d, J=9.0 Hz, 1H), 7.77 (d, J=8.5 Hz, 1H), 7.68 (d, J=1 Hz, 1H), 7.51 (s, 1H), 7.33 (dt, J=5.5, 3 Hz, 1H), 7.30 (d, J=2.5 Hz, 1H), 7.17 (dd, J=9, 2.5 Hz, 1H), 6.98 (t, J=1 Hz, 1H), 6.78 (t, J=1 Hz, 1H), 4.34-4.12 (m, 4H), 3.92 (q, J=7 Hz, 1H), 3.88 (s, 3H), 1.45 (d, J=7 Hz, 3H). 13C NMR (101 MHz, DMSO) delta 173.52, 157.19, 137.40, 135.30, 133.33, 129.15, 128.37, 128.25, 126.99, 126.20, 125.63, 119.46, 118.73, 105.69, 63.74, 55.15, 44.94, 44.35, 18.19. |
68.3% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In tetrahydrofuran; at 20℃; for 42.5h;Cooling with ice; Irradiation; | 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide-HCI (EDC-HCI) (2.20 g, 1 1.5 mmol) was added solid all at once to a magnetically stirred solution of naproxen (2.30 g, 10.0 mmol), 1-(2-hydroxyethyl)imidazole (1 .12 g, 10.0 mmol) and 4- Dimethylaminopyridine (61 mg, 0.5 mmol) in dry tetrahydrofuran (50 ml.) cooled in an ice bath and kept under nitrogen. The reaction mixture was stirred in an ice bath for 30 min and at ambient temperature. More EDC-HCI (400 mg, 2 mmol) was added after 13 hrs, 17 hrs . After stirring for 22 hrs at room temperature the mixture was concentrated and the residue partitioned between water (50 ml_), saturated NH4CI (20 ml.) and EtOAc (120 ml_). The organic layer was washed with 50 % saturated NH4CI (2 x 50 ml_), 50 % saturated NaHC03 (50 ml.) and brine (50 ml_). The organic layer was dried and concentrated. The oily residue was purified by Flash Chromatography using ethyl acetate and heptanes as eluent afforded a colourless oil (2.74 g, 84 %) after drying in high vacuum. The oil was crystallised from ether and recrystallised from Tert-butylmethylether (-20 ml_, seeded) to afford the title compound as a colourless solid (2.21 g, 68.3 %). Mp. 60.6-61.3 C. 1H NMR (400 MHz, DMSO) delta 7.80 (d, J = 9.0 Hz, 1 H), 7.77 (d, J = 8.5 Hz, 1 H), 7.68 (d, J = 1 Hz, 1 H), 7.51 (s, 1 H), 7.33 (dt, J = 5.5, 3 Hz, 1 H), 7.30 (d, J = 2.5 Hz, 1 H), 7.17 (dd, J = 9, 2.5 Hz, 1 H), 6.98 (t, J = 1 Hz, 1 H), 6.78 (t, J = 1 Hz, 1 H), 4.34 - 4.12 (m, 4H), 3.92 (q, J = 7 Hz, 1 H), 3.88 (s, 3H), 1 .45 (d, J = 7 Hz, 3H). 13C NMR (101 MHz, DMS0) 5 173.52, 157.19, 137.40, 135.30, 133.33, 129.15, 128.37, 128.25, 126.99, 126.20, 125.63, 1 19.46, 1 18.73, 105.69, 63.74, 55.15, 44.94, 44.35, 18.19. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
86.15% | With dmap; dicyclohexyl-carbodiimide In chloroform at 20℃; | 3 Synthesis of 11, 17 dihydroxy-21-(2-(6-methoxynaphthalene-2yl) propionoxy)-pregn-4-ene-3, 20-dione 4.0 mg (0.011 mmol) of compound 2 (11,17,21-tri-hydroxy-3,20-diketo-pregn-4-ene), dissolved in 2.5 mL of chloroform and 2.5 mg(0.011 mmol) of naproxen was added followed by the addition of1.34 mg (0.011 mmol) of DMAP and 2.2 mg (0.011 mmol) of DCC.The reaction mixture was stirred at room temperature until reactionwascomplete. Progress of reactionwas monitored by thin layerchromatography. N, N0 dicyclohexyl urea (DCU) formed as byproduct was filtered off and the filtratewas treated with 5% HCl andwater, dried over anhydrous sodium sulphate. Chloroform wasdistilled off under reduced pressure. The crude product obtainedwas subjected to column chromatography for purification of synthesizedcompound using silica gel (60e120 mesh) as absorbent and chloroform/methanol (98:2) as eluent yielding 5.6 mg (86.15%)of compound 4 as white crystalline solid. m.p: 482 K, Molecularformula: C35H42O7, 1H NMR in CDCl3 at 300 MHz (ppm): d 7.260 (D,s, CDCl3), d 0.961 (1H, s, H-18), d 1.013e0.976 (1H, dd, H-9, J 3.3Hz), d 1.446 (1H, s, H-19), d 1.624 (3H, d, H-24, J 7.2), d 3.911 (3H, s,CH3-35), d3.959 (1H, q, H-23, J 6.9 Hz, 7.2 Hz), d 4.428e4.408 (1H,q, J 3 Hz, H-11), d 4.800 (1H, d, J 17.4, H-21A), d 5.046 (1H, d,J 17.1, H-21B), d 5.676 (1H, d, H-4, J 1.2), d 7.120 (1H, s, H-28),d 7.149 (1H, d, H-30, J 2.7), d 7.451e7.417 (1H, dd, H-26, J 1.8 Hz),d 7.698 (2H, d, H-31, H-32, J 1.8 Hz), d 7.726 (1H,d. H-27,J 2.4 Hz). FT-IR nmax (in cm1): 3486, 2948, 2922, 2870, 2850,1729, 1654, 1608, 1507, 1484, 1458, 1389, 1367, 1324, 12651, 1229,1181, 1030, 893, 858, 812, 753, 669. ESI-MS: 575, 574, 557, 539, 362,345, 302. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
73.84% | With dmap; dicyclohexyl-carbodiimide In chloroform at 20℃; | 5 Synthesis of 21-(2-(6-methoxynaphthalene-2-yl) propionoxy)11, 17-di-hydroxy-3, 20-diketo-pregn-1, 4-diene 4.0 mg (0.011 mmol) of 11, 17, 21-tri-hydroxy-3, 20-diketopregn-1, 4-diene (3) was dissolved in 2 mL of chloroform and thennaproxen 2.5 mg (0.011 mmol), DCC 2.2 mg (0.011 mmol) andDMAP 1.34 mg (0.011 mmol) were added. The reaction mixturewasstirred at room temperature. The completion of reaction wasmonitored with the help of thin layer chromatography (TLC). Reactionmixture was washed with 5% HCl and water, dried overanhydrous sodium sulphate and filtered. The organic layer wasconcentrated under reduced pressure and the crude concentratedproduct was purified by column-chromatography using ethyl acetate:hexane (2:98) yielding 4.8 mg (73.84%) of 6 as amorphous.m.p 462 K, Molecular formula: C35H40O7, 1H NMR at 300 MHz (inDMSO-d6) dppm: 7.80 (3H, d, H-27, H-31 & H-32, J 9.6 Hz), 7.45(1H, d, H-26, J 8.4 Hz), 7.32 (2H, d, H-30 & H-28, J 9.0 Hz), 7.17(1H, d, H-1, J 9.0 Hz), 6.13 (1H, d, H-2, J 10.2 Hz), 5.91 (1H, s, H-4), 5.38 4.90 (1H, br s, H-17(OH)), 5.07 (1H, d, H-21A, J 17.7 Hz), 4.72 (1H, d, H-21B, J 17.7 Hz), 4.26 (1H, br s, H-11), 4.01 (1H, q, H-23), 3.86 (3H, s, CH3-35), 1.52 (3H, d, H-24, J 6.9 Hz), 1.38 (3H, s,CH3-19), 0.85 (3H, s, CH3-18), 0.88 (6H, d, CH3-33 & CH3-34, J 6.6Hz). IR (KBr) nmax (cm1): 3415, 2930, 2853, 1724,1656, 1607, 1452,1391, 1265, 1232, 1174, 1033, 888, 818. ESI-MS: m/z 572 [M], m/z574 [M2], m/z 537, m/z 324. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
88% | With dmap; 1-ethyl-(3-(3-dimethylamino)propyl)-carbodiimide hydrochloride; In dichloromethane; at 20℃; for 2h; | To a solution of 2-(4-((tert-butyldimethyl silyl)oxy)-2-methylbutan-2-yl)-3 , 5 -dimethylphenol (21, 1.27 g, 3.9mmol), (S)-2-(6-methoxynaphthalen-2-yl)propanoic acid (1.00 g, 4.4 mmol) and DMAP (100 mg, 0.8 mmol) in dichloromethane (50 mL) was added EDC (1.62 g, 8.7 mmol). The mixture was stirred at room temperature for 2 h, then quenched with the addition of H20 (50 mL), and extracted with dichloromethane (2x50 mL). The combined organic phase was dried over Na2504 and evaporated under reduced pressure to give the crude product, which was purifiedby chromatography to give a colorless oil (1.86 g, 88%). ?HNMR (400 IVIFIz CDC13): 7.80-7.74 (m, 3H), 7.53 (dd, J 8.4 Hz, J 1.6 Hz, 1H), 7.20-7.16 (m, 2H), 6.77 (d, J= 1.2 Hz,1H), 6.36 (d, J = 1.2 Hz, 1H), 4.07 (q, , J= 7.2 Hz, 1H), 3.93 (s, 3H), 3.43 (t, J= 7.2 Hz, 2H),2.50 (s, 3H), 2.17 (s, 3H), 1.94 (t, J = 7.2 Hz, 2H), 1.72 (d, J 7.2 Hz, 3H), 1.39 (d, J 7.2Hz, 6H), 0.87 (s, 9H), -0.02 (s, 6H); ?3C NIVIR (CDC13): 173.7, 157.8, 150.2, 138.3, 136.0,134.9, 134.2, 134.0, 132.3, 129.5, 129.1, 127.4, 126.6, 126.5, 122.7, 119.2, 105.7, 60.9, 55.4,46.3, 45.9, 39.2, 31.9, 31.9, 26.1, 25.4, 20.3, 18.6, 18.3, -5.2. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
With Yarrowia lipolytica Lip2p lipase; In decane; at 20℃; for 100h;Enzymatic reaction;Kinetics; | General procedure: In a 2 mL reactor (Eppendorf), 750 lL of culture supernatant (or the concentrate supernatant) containing the enzyme and 750 lL ofracemic ethyl ibuprofen, naproxen or ketoprofen (50 mM indecane) were added. The reactors were stirred in a vortex Genie2 (D. Dutscher, Brumat, France) at room temperature for 100 h.At regular time intervals, the progress of the reaction was monitored by analyzing the organic phase composition after phase separationby centrifugation (dilution 1, 10 and 30 in hexane for the ibuprofen, naproxen and ketoprofen ester, respectively). |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
42% | To the solution of (naproxen, 230mg 1.0mmol) in 8mL of acetonitrile, DMAP (18mg, 0.15mmol) and EDCI (190mg, 1.0mmol) were added with stirring at room temperature for 0.5h. To the reaction mixture <strong>[25984-63-8]4-hydroxythiobenzamide</strong> (153mg, 1.0mmol) was added and stirred for 4hat room temperature. After filtration, the filtrate was evaporated under reduced pressure to remove the solvent. The oily residue thus obtained was dissolved in trichloromethane; the organic layer was washed with brine, with NaCl 5%, and then dried on anhydrous Na2SO4, filtered and the solvent evaporated. The crude product was chromatographed on a silica gel (CHCl3/CH3OH 30:1), and 148.8mg pale yellow solid was obtained. Yield: 42.0%. IR (KBr, cm-1): 3398 (w, NH2), 3298 (w, NH2), 1755 (v, COO), 1214 (s, COC), 1170 (v, C=S). 1H NMR (DMSO-d6, TMS, ppm): delta 1.59 (d, J=7.2Hz, 3H, Ar-C-CH3), 3.88 (s, 3H, O-CH3), 4.25 (q, J=7.2Hz, 1H, Ar-CH), 7.09 (d, J=8.8Hz, 2H, Ar-H), 7.18 (dd, J=8.8Hz, 2.4Hz, 1H, Ar-H), 7.33 (s, 1H, Ar-H), 7.52 (d, J=8.4Hz, 1H, Ar-H), 7.85 (d, J=4.4Hz, 2H, Ar-H), 7.87 (s, 1H, Ar-H), 7.90 (d, J=8.4Hz, 2H, Ar-H), 9.53 (s, 1H, NH), 9.91 (s, 1H, NH). 13C NMR (DMSO-d6, TMS, ppm): delta18.9, 45.0, 55.7, 106.3, 119.4, 121.5, 126.4, 126.7, 127.8, 129.0, 129.3, 129.7, 133.9, 135.6, 153.2, 157.8, 173.1. ESI-HRMS (m/z): calcd. for C21H19NO3SNa [M+Na]+: 388.0983; found 388.0979. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
92% | Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With 1,1'-carbonyldiimidazole In acetonitrile at 20℃; for 0.5h; Stage #2: 4-chlorobenzamidoxime In acetonitrile for 3h; | 1 4.1.1 General procedure for the synthesis of N'-[2-(6-Methoxy-2-naphthyl) propanoyl]oxy}aryl carboximidamides (3b-g) General procedure: To a solution of naproxen 1 (10 mmole, 1.2g) in 30ml acetonitrile, the N,N'-carbonyldiimidazole CDI (11 mmole, 1.2g) was added and the mixture was stirred at room temperature for 30min. The respective amidoximes 2b-g (10 mmole) was then added and stirred for further 3 hrs. After completion of reaction (monitored with TLC), the formed precipitate 3b-g was collected by filtration, washed several times with acetonitrile, dried and used without further purification. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
89% | Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With 1,1'-carbonyldiimidazole In acetonitrile at 20℃; for 0.5h; Stage #2: 4-chlorobenzamidoxime In acetonitrile for 27h; Reflux; | 1 4.1.2 General procedure for the synthesis of 5-[1-(6-Methoxy-2-naphthyl)ethyl]-3-aryl-1,2,4-oxadiazole (4b-g) General procedure: To a solution of naproxen 1 (10 mmole, 1.2g) in 30ml acetonitrile, the N,N'-carbonyldiimidazole CDI (11 mmole, 1.2g) was added and the mixture was stirred at room temperature for 30 mins. The respective amidoximes 2b-g (10 mmole) was then added and stirred 3 hrs. After that, the reaction mixture was refluxed for 24 hrs (monitored with TLC) and cooled to room temperature. The formed precipitate 4b-g was collected by filtration, dried and recrystallized from ethanol. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
91% | Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With 1,1'-carbonyldiimidazole In acetonitrile at 20℃; for 0.5h; Stage #2: 4-methoxybenzamidoxime In acetonitrile for 3h; | 2 4.1.1 General procedure for the synthesis of N'-[2-(6-Methoxy-2-naphthyl) propanoyl]oxy}aryl carboximidamides (3b-g) General procedure: To a solution of naproxen 1 (10 mmole, 1.2g) in 30ml acetonitrile, the N,N'-carbonyldiimidazole CDI (11 mmole, 1.2g) was added and the mixture was stirred at room temperature for 30min. The respective amidoximes 2b-g (10 mmole) was then added and stirred for further 3 hrs. After completion of reaction (monitored with TLC), the formed precipitate 3b-g was collected by filtration, washed several times with acetonitrile, dried and used without further purification. |
With 1,1'-carbonyldiimidazole at 20℃; |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
87% | Stage #1: (2S)-2-(6-methoxy(2-naphthyl))propanoic acid With 1,1'-carbonyldiimidazole In acetonitrile at 20℃; for 0.5h; Stage #2: 4-methoxybenzamidoxime In acetonitrile for 27h; Reflux; | 2 4.1.2 General procedure for the synthesis of 5-[1-(6-Methoxy-2-naphthyl)ethyl]-3-aryl-1,2,4-oxadiazole (4b-g) General procedure: To a solution of naproxen 1 (10 mmole, 1.2g) in 30ml acetonitrile, the N,N'-carbonyldiimidazole CDI (11 mmole, 1.2g) was added and the mixture was stirred at room temperature for 30 mins. The respective amidoximes 2b-g (10 mmole) was then added and stirred 3 hrs. After that, the reaction mixture was refluxed for 24 hrs (monitored with TLC) and cooled to room temperature. The formed precipitate 4b-g was collected by filtration, dried and recrystallized from ethanol. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
74% | With dicyclohexyl-carbodiimide; In N,N-dimethyl acetamide; acetone; | The round bottom flask is loaded with 28.35 g of <strong>[58-56-0]pyridoxine hydrochloride</strong> II, 95.23 g of naproxene III, 50.52 g of 4-N,N-dimethylaminopyridine and 123.73 g of dicyclohexyl carbodiimide in 5 l of acetone. The reaction mixture is stirred until the formation of the dicyclohexyl urea precipitate is stopped, then the precipitate is filtered, washed with 200 ml of acetone and the combined leachate is evaporated in a vacuum. The product is purified with column chromatography on silica gel (eluent ethyl acetate-petroleum ether 1:1). Product IV is obtained in the form of white crystalline substance (yield 82.0 g, 74%). In more detail, the preparation of this compound and its properties are described in the invention under the patent RU 2513098. |
Yield | Reaction Conditions | Operation in experiment |
---|---|---|
27% | With 2,4,6-trimethyl-pyridine; ammonium peroxydisulfate; cyclohexa-1,4-diene In dimethylsulfoxide-d6 at 60℃; for 2h; Sealed tube; Inert atmosphere; |
Tags: 22204-53-1 synthesis path| 22204-53-1 SDS| 22204-53-1 COA| 22204-53-1 purity| 22204-53-1 application| 22204-53-1 NMR| 22204-53-1 COA| 22204-53-1 structure
Precautionary Statements-General | |
Code | Phrase |
P101 | If medical advice is needed,have product container or label at hand. |
P102 | Keep out of reach of children. |
P103 | Read label before use |
Prevention | |
Code | Phrase |
P201 | Obtain special instructions before use. |
P202 | Do not handle until all safety precautions have been read and understood. |
P210 | Keep away from heat/sparks/open flames/hot surfaces. - No smoking. |
P211 | Do not spray on an open flame or other ignition source. |
P220 | Keep/Store away from clothing/combustible materials. |
P221 | Take any precaution to avoid mixing with combustibles |
P222 | Do not allow contact with air. |
P223 | Keep away from any possible contact with water, because of violent reaction and possible flash fire. |
P230 | Keep wetted |
P231 | Handle under inert gas. |
P232 | Protect from moisture. |
P233 | Keep container tightly closed. |
P234 | Keep only in original container. |
P235 | Keep cool |
P240 | Ground/bond container and receiving equipment. |
P241 | Use explosion-proof electrical/ventilating/lighting/equipment. |
P242 | Use only non-sparking tools. |
P243 | Take precautionary measures against static discharge. |
P244 | Keep reduction valves free from grease and oil. |
P250 | Do not subject to grinding/shock/friction. |
P251 | Pressurized container: Do not pierce or burn, even after use. |
P260 | Do not breathe dust/fume/gas/mist/vapours/spray. |
P261 | Avoid breathing dust/fume/gas/mist/vapours/spray. |
P262 | Do not get in eyes, on skin, or on clothing. |
P263 | Avoid contact during pregnancy/while nursing. |
P264 | Wash hands thoroughly after handling. |
P265 | Wash skin thouroughly after handling. |
P270 | Do not eat, drink or smoke when using this product. |
P271 | Use only outdoors or in a well-ventilated area. |
P272 | Contaminated work clothing should not be allowed out of the workplace. |
P273 | Avoid release to the environment. |
P280 | Wear protective gloves/protective clothing/eye protection/face protection. |
P281 | Use personal protective equipment as required. |
P282 | Wear cold insulating gloves/face shield/eye protection. |
P283 | Wear fire/flame resistant/retardant clothing. |
P284 | Wear respiratory protection. |
P285 | In case of inadequate ventilation wear respiratory protection. |
P231 + P232 | Handle under inert gas. Protect from moisture. |
P235 + P410 | Keep cool. Protect from sunlight. |
Response | |
Code | Phrase |
P301 | IF SWALLOWED: |
P304 | IF INHALED: |
P305 | IF IN EYES: |
P306 | IF ON CLOTHING: |
P307 | IF exposed: |
P308 | IF exposed or concerned: |
P309 | IF exposed or if you feel unwell: |
P310 | Immediately call a POISON CENTER or doctor/physician. |
P311 | Call a POISON CENTER or doctor/physician. |
P312 | Call a POISON CENTER or doctor/physician if you feel unwell. |
P313 | Get medical advice/attention. |
P314 | Get medical advice/attention if you feel unwell. |
P315 | Get immediate medical advice/attention. |
P320 | |
P302 + P352 | IF ON SKIN: wash with plenty of soap and water. |
P321 | |
P322 | |
P330 | Rinse mouth. |
P331 | Do NOT induce vomiting. |
P332 | IF SKIN irritation occurs: |
P333 | If skin irritation or rash occurs: |
P334 | Immerse in cool water/wrap n wet bandages. |
P335 | Brush off loose particles from skin. |
P336 | Thaw frosted parts with lukewarm water. Do not rub affected area. |
P337 | If eye irritation persists: |
P338 | Remove contact lenses, if present and easy to do. Continue rinsing. |
P340 | Remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P341 | If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P342 | If experiencing respiratory symptoms: |
P350 | Gently wash with plenty of soap and water. |
P351 | Rinse cautiously with water for several minutes. |
P352 | Wash with plenty of soap and water. |
P353 | Rinse skin with water/shower. |
P360 | Rinse immediately contaminated clothing and skin with plenty of water before removing clothes. |
P361 | Remove/Take off immediately all contaminated clothing. |
P362 | Take off contaminated clothing and wash before reuse. |
P363 | Wash contaminated clothing before reuse. |
P370 | In case of fire: |
P371 | In case of major fire and large quantities: |
P372 | Explosion risk in case of fire. |
P373 | DO NOT fight fire when fire reaches explosives. |
P374 | Fight fire with normal precautions from a reasonable distance. |
P376 | Stop leak if safe to do so. Oxidising gases (section 2.4) 1 |
P377 | Leaking gas fire: Do not extinguish, unless leak can be stopped safely. |
P378 | |
P380 | Evacuate area. |
P381 | Eliminate all ignition sources if safe to do so. |
P390 | Absorb spillage to prevent material damage. |
P391 | Collect spillage. Hazardous to the aquatic environment |
P301 + P310 | IF SWALLOWED: Immediately call a POISON CENTER or doctor/physician. |
P301 + P312 | IF SWALLOWED: call a POISON CENTER or doctor/physician IF you feel unwell. |
P301 + P330 + P331 | IF SWALLOWED: Rinse mouth. Do NOT induce vomiting. |
P302 + P334 | IF ON SKIN: Immerse in cool water/wrap in wet bandages. |
P302 + P350 | IF ON SKIN: Gently wash with plenty of soap and water. |
P303 + P361 + P353 | IF ON SKIN (or hair): Remove/Take off Immediately all contaminated clothing. Rinse SKIN with water/shower. |
P304 + P312 | IF INHALED: Call a POISON CENTER or doctor/physician if you feel unwell. |
P304 + P340 | IF INHALED: Remove victim to fresh air and Keep at rest in a position comfortable for breathing. |
P304 + P341 | IF INHALED: If breathing is difficult, remove victim to fresh air and keep at rest in a position comfortable for breathing. |
P305 + P351 + P338 | IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing. |
P306 + P360 | IF ON CLOTHING: Rinse Immediately contaminated CLOTHING and SKIN with plenty of water before removing clothes. |
P307 + P311 | IF exposed: call a POISON CENTER or doctor/physician. |
P308 + P313 | IF exposed or concerned: Get medical advice/attention. |
P309 + P311 | IF exposed or if you feel unwell: call a POISON CENTER or doctor/physician. |
P332 + P313 | IF SKIN irritation occurs: Get medical advice/attention. |
P333 + P313 | IF SKIN irritation or rash occurs: Get medical advice/attention. |
P335 + P334 | Brush off loose particles from skin. Immerse in cool water/wrap in wet bandages. |
P337 + P313 | IF eye irritation persists: Get medical advice/attention. |
P342 + P311 | IF experiencing respiratory symptoms: call a POISON CENTER or doctor/physician. |
P370 + P376 | In case of fire: Stop leak if safe to Do so. |
P370 + P378 | In case of fire: |
P370 + P380 | In case of fire: Evacuate area. |
P370 + P380 + P375 | In case of fire: Evacuate area. Fight fire remotely due to the risk of explosion. |
P371 + P380 + P375 | In case of major fire and large quantities: Evacuate area. Fight fire remotely due to the risk of explosion. |
Storage | |
Code | Phrase |
P401 | |
P402 | Store in a dry place. |
P403 | Store in a well-ventilated place. |
P404 | Store in a closed container. |
P405 | Store locked up. |
P406 | Store in corrosive resistant/ container with a resistant inner liner. |
P407 | Maintain air gap between stacks/pallets. |
P410 | Protect from sunlight. |
P411 | |
P412 | Do not expose to temperatures exceeding 50 oC/ 122 oF. |
P413 | |
P420 | Store away from other materials. |
P422 | |
P402 + P404 | Store in a dry place. Store in a closed container. |
P403 + P233 | Store in a well-ventilated place. Keep container tightly closed. |
P403 + P235 | Store in a well-ventilated place. Keep cool. |
P410 + P403 | Protect from sunlight. Store in a well-ventilated place. |
P410 + P412 | Protect from sunlight. Do not expose to temperatures exceeding 50 oC/122oF. |
P411 + P235 | Keep cool. |
Disposal | |
Code | Phrase |
P501 | Dispose of contents/container to ... |
P502 | Refer to manufacturer/supplier for information on recovery/recycling |
Physical hazards | |
Code | Phrase |
H200 | Unstable explosive |
H201 | Explosive; mass explosion hazard |
H202 | Explosive; severe projection hazard |
H203 | Explosive; fire, blast or projection hazard |
H204 | Fire or projection hazard |
H205 | May mass explode in fire |
H220 | Extremely flammable gas |
H221 | Flammable gas |
H222 | Extremely flammable aerosol |
H223 | Flammable aerosol |
H224 | Extremely flammable liquid and vapour |
H225 | Highly flammable liquid and vapour |
H226 | Flammable liquid and vapour |
H227 | Combustible liquid |
H228 | Flammable solid |
H229 | Pressurized container: may burst if heated |
H230 | May react explosively even in the absence of air |
H231 | May react explosively even in the absence of air at elevated pressure and/or temperature |
H240 | Heating may cause an explosion |
H241 | Heating may cause a fire or explosion |
H242 | Heating may cause a fire |
H250 | Catches fire spontaneously if exposed to air |
H251 | Self-heating; may catch fire |
H252 | Self-heating in large quantities; may catch fire |
H260 | In contact with water releases flammable gases which may ignite spontaneously |
H261 | In contact with water releases flammable gas |
H270 | May cause or intensify fire; oxidizer |
H271 | May cause fire or explosion; strong oxidizer |
H272 | May intensify fire; oxidizer |
H280 | Contains gas under pressure; may explode if heated |
H281 | Contains refrigerated gas; may cause cryogenic burns or injury |
H290 | May be corrosive to metals |
Health hazards | |
Code | Phrase |
H300 | Fatal if swallowed |
H301 | Toxic if swallowed |
H302 | Harmful if swallowed |
H303 | May be harmful if swallowed |
H304 | May be fatal if swallowed and enters airways |
H305 | May be harmful if swallowed and enters airways |
H310 | Fatal in contact with skin |
H311 | Toxic in contact with skin |
H312 | Harmful in contact with skin |
H313 | May be harmful in contact with skin |
H314 | Causes severe skin burns and eye damage |
H315 | Causes skin irritation |
H316 | Causes mild skin irritation |
H317 | May cause an allergic skin reaction |
H318 | Causes serious eye damage |
H319 | Causes serious eye irritation |
H320 | Causes eye irritation |
H330 | Fatal if inhaled |
H331 | Toxic if inhaled |
H332 | Harmful if inhaled |
H333 | May be harmful if inhaled |
H334 | May cause allergy or asthma symptoms or breathing difficulties if inhaled |
H335 | May cause respiratory irritation |
H336 | May cause drowsiness or dizziness |
H340 | May cause genetic defects |
H341 | Suspected of causing genetic defects |
H350 | May cause cancer |
H351 | Suspected of causing cancer |
H360 | May damage fertility or the unborn child |
H361 | Suspected of damaging fertility or the unborn child |
H361d | Suspected of damaging the unborn child |
H362 | May cause harm to breast-fed children |
H370 | Causes damage to organs |
H371 | May cause damage to organs |
H372 | Causes damage to organs through prolonged or repeated exposure |
H373 | May cause damage to organs through prolonged or repeated exposure |
Environmental hazards | |
Code | Phrase |
H400 | Very toxic to aquatic life |
H401 | Toxic to aquatic life |
H402 | Harmful to aquatic life |
H410 | Very toxic to aquatic life with long-lasting effects |
H411 | Toxic to aquatic life with long-lasting effects |
H412 | Harmful to aquatic life with long-lasting effects |
H413 | May cause long-lasting harmful effects to aquatic life |
H420 | Harms public health and the environment by destroying ozone in the upper atmosphere |
Sorry,this product has been discontinued.
Home
* Country/Region
* Quantity Required :
* Cat. No.:
* CAS No :
* Product Name :
* Additional Information :